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ORIGINAL ARTICLE
Background/Aims: Darbepoetin alfa (DPO) exhibits comparable renoprotective effects to erythropoietin (EPO)
in several animal models of acute renal injury. We examined whether DPO also attenuated renal injury in a rat
model of cisplatin nephrotoxicity. 
Methods: Male Spague-Dawley rats were divided into four groups: untreated, DPO-treated, cisplatin-injected,
and DPO-treated cisplatin-injected. DPO pretreatment was conducted 24 hours after and just before cisplatin
administration. Ninety-six hours after cisplatin administration, animals in all experimental groups were sacrificed.
We examined serology; real-time reverse transcription polymerase chain reaction (RT-PCR) for TNF-α, Bcl-2, and
MCP-1 gene expression; and Western blots for caspase-3. We also conducted terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and light microscopy. 
Results: Pretreatment with DPO significantly reduced the levels of blood urea nitrogen and serum creatinine, the
magnitude of renal tubular epithelial damage, and renal gene expression of TNF-α, Fas, and MCP-1 in kidneys
injured by cisplatin. Pretreatment with DPO significantly increased Bcl-2 mRNA levels in kidneys injured by
cisplatin, and significantly reduced activated caspase-3 and TUNEL-positive cells.
Conclusions: DPO exhibits a renoprotective effect in experimental cisplatin-induced renal injury, the mechanism of
which may involve DPO antiinflammatory and antiapoptotic effects. (Korean J Intern Med 2009;24:238-246)
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INTRODUCTION
Cisplatin is one of the most effective anti-neoplastic
agents used for treatment of various malignancies.
However, 25-35% of patients who receive cisplatin experi-
ence nephrotoxicity to a varying degree [1]. Cisplatin
causes tubular injury through multiple mechanisms,
including hypoxia, oxidative stress, inflammation, and
apoptosis. Furthermore, significant interactions among
these various pathways may occur in cisplatin injury [2-6]. 
Recently, erythropoietin (EPO) was found to reduce
injury caused by ischemiareperfusion in the brain, liver,
heart, and kidney [7-10], and injury caused by cisplatin
and cyclosporine [11,12]. EPO has anti-apoptic and anti-
inflammatory properties that protect tissues and enhance
the regeneration of tubular epithelial.
Darbepoetin alfa (DPO), an erythropoietic agent with a
serum half-life three times as long as EPO, exhibits similar
protective effects [13] as well as hematopoietic effects, and
attenuates renal ischemia-reperfusion injury in rats [14]. 
However, this compound has not yet been studied in
cisplatin nephrotoxicity models in vivo. Thus, we examined
whether DPO could attenuate cisplatin nephrotoxicity. We
also examined the role of anti-apoptotic and antiinflam-
matory mechanisms in attenuating renal injury by DPO.Choi DE, et al. DPO Attenuates Cisplatin-Induced Nephrotoxicity    239
METHODS
Animals and drug treatment
All experiments were performed on 8-week-old male
Sprague-Dawley (SD) rats (weighing 250-260 g; Korea
Research Institute of Bioscience and Biotechnology,
Daejeon, Korea). The rats were given a standard laboratory
diet and water. Rats were cared for under a protocol
approved by the Institutional Animal Care and Use
Committee of the Chungnam National University Medical
School.
We divided the rats into four groups: untreated (n=7),
DPO-treated (n=7), cisplatin- injected (n=12), and DPO-
treated cisplatin-injected (n=12) groups. The four groups
were administered a single intraperitoneal injection of
vehicle or cisplatin (5 mg/kg, Choongwae Pharma Co,
Seoul, Korea). For the vehicle, 0.9% NaCl was administered
in the same manner and volume. DPO treatment was
performed with Darbepoetin (25 µg/kg once; Aranesp
®,
Amgen, Thousand Oaks, CA, USA), administered
intraperitoneally 24 hours before cisplatin injection and
just before cisplatin injection. The animals were sacrificed
under anesthesia, by intraperitoneal administration of a
mixture of ketamine (50 mg/mL, 10 mg/kg, Ketalar;
Bayer, Leverkusen, Germany) and xylazine (2%, 0.1
mL/kg, Rompun; Bayer) in solution (2 mL/kg).
Tissue preparation
At the end of the study (96 hours after cisplatin
injection), rats were anesthetized as described above. Both
kidneys were excised immediately, and cut into three
coronal sections. Two pieces of kidney were snap-frozen in
liquid nitrogen, and stored at -70˚C for subsequent RNA
extraction and protein analysis; the other piece was fixed
in 10% buffered formaldehyde at room temperature, and
then embedded in Paraplast (Sherwood Medical, St.
Louis, MO, USA) for light microscopy and terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL).
Light microscopy examination
Pieces of kidney embedded in Paraplast were cut into 4-
µm sections and mounted on glass slides. The sections
were then deparaffinized with xylene, counterstained with
hematoxylin and eosin (H&E), and examined under a
light microscope (200× magnification, Dialux 22; Leitz,
Milan, Italy). We evaluated necrosis, vacuolation, and
desquamation of epithelial cells in renal tubules 96 h after
cisplatin treatment. Five different fields of the renal outer-
medular area of every slide were examined by a renal
pathologist blind to the study groups. The magnitude of
damage of tubular epithelial cells was examined in
periodic acid Schiff (PAS)-stained sections, counting the
numbers of tubules that were injured greater than 50% in
the outer medulla.
RNA extraction, semi-quantitative RT-PCR and
real-time PCR
Kidney sections stored at -70˚C were used for RNA
extraction. Total RNA was extracted using the RNeasy
Mini Kit (QIAGEN, Hilden, Germany). cDNA was
synthesized from 1 µg total RNA, using an oligo dT primer
(Amersham Pharmacia, Piscataway, NJ, USA), dNTPs
(Amersham Pharmacia), M-MLV reverse transcriptase
(Gibco-BRL, Grand Island, NY, USA), 0.1 M DTT, and
buffers, in a volume of 20 µL. The 20-µL cDNA reaction
mix was diluted to a total volume of 100 µL. Polymerase
chain reaction (PCR) was then used to amplify the
following specific cDNAs: GAPDH (primers: sense 5’TCC
CAG ACC CCA TAA CAA CAG-3’ and antisense 5’-TGA
GGG TGC AGC GAA CTT TA3’), TNF-α (primers: sense 5’
GTT GCC TCC CCC TTT TCT TT-3’ and antisense 5’-CCT
GGT CAC CAA ATC AGC ATT-3’), Fas (primers: sense 5’-
CTG TCC TGC CTC TGG TGC TTG3’ and antisense 5’-
ACG AAC GCT CCT CTT CAA CTC C-3’), Bcl-2 (primers:
sense 5’ACG GTG GTG GAG GAA CTC TTC-3’ and
antisense 5’ACA CAT GAC CCC ACC GAA CT3’), and
MCP1 (primers: sense 5’-ATG CAG GTC TCT GTC ACG-3’
and antisense 5’-ATG GTT CTC TGT CAT ACT-3’). PCR
was performed using SYBR Green PCR mastermix
(Applied by Qiagen). The amplification reaction volume
was 20 µL, consisting of 10 µL iQ SYBR Green PCR
mastermix, 1 µL primers, 1 µL cDNA, and 8 µL water.
Amplification and detection were performed using a
thermal cycler (Rotor-Gene 6000, Corbett Research,
Mortlake, Australia). PCR conditions were as follows:
denaturation at 95˚C for 10 minutes, followed by 40
cycles of 10 seconds at 95˚C, 15 seconds at annealing
temperature (60˚C for GAPDH, TNF-α, Fas, Bcl-2, MCP-
1), and 20 seconds at 72˚C. SYBR green fluorescence was
measured at the end of each cycle using the comparative
threshold cycle (Ct) method. The cDNA was quantified
using the following formula for each group of data:
2-∆∆Ct = 2-[(Ct of target gene - Ct of GAPDH in DPO only-treated
rat, IR rat, and DPO-treated cisplatin rat)
- (Ct of target gene - Ct of GAPDH in untreated rat)].240 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
Western blotting
Kidney sections stored at 70˚C were homogenized in
Protein Extraction solution (PRO-PREP, iNtRON,
Sungnam-si, Korea). Homogenates were centrifuged
(12,000×g, 15 minutes, 4˚C) and protein concentrations
were determined in supernatants using the Bradford
method protein microassay (BioRad, Hercules, CA, USA).
The cleared supernatants were mixed with the same
volume of 2× SDS sample buffer (62.5 mM, Tris-HCl (pH
6.8), 6% (w/v) SDS, 30% glycerol, 125 mM DTT, 0.3%
(w/v) bromophenol blue), so that the final concentration
of the mixture was 1× (500 µg/100 µL). The homogenates
were boiled at 94˚C for 5 minutes in Laemmli sample
buffer. Then, 40 µg total protein was loaded in a stacking
polyacrylamide gel and resolved on an 8%+15%
polyacrylamide gel with biotinylated molecular weight
standard markers. The samples were then wet-transferred
to a 0.2-micron nitrocellulose membrane (Amersham
Pharmacia). The nitrocellulose membrane was stained
with Coomassie blue to assess the equal loading of
protein. Subsequently, the blots were blocked for 1 hour
with 5% non-fat dry milk in TBST buffer (20 mM TrisHCl
(pH 7.6), 0.8% NaCl, 0.05% Tween 20) and incubated
overnight at 4˚C with a cleaved-caspase 3 antibody
(1:1000 dilution; Cell Signaling Technology, Beverly, MA,
USA), and a β-actin antibody (1:1000 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). After washing in
TBST, the blots were incubated with secondary anti-rabbit
IgG-HRP-linked antibody (1:1000 dilution; Cell Signaling
Technology) for 1 hour. The blots were washed again in
TBST and the bands were detected using enhanced
chemiluminescence (Millipore, Billerica, MA, USA), and
exposed to films. The optical density for quantification
was determined using Gel-Pro Analyzer version 3.1
(Media Cybernetics, Silver Spring, MD, USA).
TUNEL
TUNEL was performed using the in situ Apoptosis
Detection Kit (S7100-KIT; Chemicon). The procedure was
modified from the manufacturer’s protocol. Briefly, 4-µm-
thick paraffin-embedded sections were dewaxed in three
changes of xylene for 10 minutes each. Rehydration was
achieved through a graded series of alcohols, from absolute
to 95%, 80%, and 70% alcohol to water. After rinsing in
PBS for 5 minutes, the sections were incubated in 0.3%
H2O2 at room temperature to eliminate endogenous
peroxidase activity. The sections were then washed in two
changes of distilled water for 5 minutes each, followed by
PBS for another 5 minutes. Proteinase K (10 µg/mL in 0.1
M Tris, 50 mM EDTA, pH 8) was applied to the sections,
and incubated for 15 minutes at room temperature. After
washing in four changes of distilled water for 2 minutes
each, and one change of PBS for 5 minutes, two drops of
equilibration buffer were applied to the sections for 0.5 to
1 minutes to facilitate pene-tration of terminal dUTP
transferase, the TdT enzyme. A reaction mixture was
prepared by mixing the reaction buffer and TdT enzyme at
5:1. Then this reaction mixture was applied to the sections,
which were incubated in a humidified chamber for 1 hour
at 37˚C to allow extension of the nick ends of the DNA
fragments with digoxigenin-dUTP. During the incubation
process, coverslips were put on the sections to prevent
them from drying out. After the incubation, the coverslips
were removed carefully without disturbing the tissues,
Figure 1. Effect of DPO on renal function in cisplatin-injected rats. Values are expressed as mean±standard deviation (SD). C, saline
control; DPO, erythropoietin only; CIS, cisplatin; CIS+DPO, DPO-treated cisplatin-injected group. *p<0.01 vs. saline, 
†p<0.01 vs. cisplatin.
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and the sections were washed in stop buffer (1 mL stock in
the kit + 34 mL distilled water) for 30 minutes at 37˚C.
After washing in PBS for 5 minutes, two drops of
peroxidase-conjugated anti-DIG antibody were applied to
the sections for 30 minutes at room temperature. After
rinsing in three changes of PBS, followed by one change in
Tris buffer, color was developed using 0.05% DAB with
0.006% H2O2 as a substrate. The sections were then
washed in water, counterstained with methyl green,
dehydrated through a graded alcohol series, cleared in
xylene, and finally mounted with Permount for observation
under a light microscope. For negative controls, distilled
Figure 2. Effect of DPO on renal histology in cisplatin-
injected rats. (A) Renal histological changes 96 h after
cisplatin administration (C, saline control; DPO,
erythropoietin only; CIS, cisplatin; CIS+DPO, DPO-
treated cisplatin-injected group). The cisplatin-injected
kidneys showed marked injury with sloughing of
tubular epithelial cells, loss of brush border, and dilation
of tubules. These changes were significantly reduced by
DPO treatment. Magnification, 200×. (B) Percentage
of damaged tubules. * p<0.01 vs. saline,
† p<0.01 vs.
cisplatin.
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water was used instead of the TdT enzyme. 
Statistical analyses
Data are reported as means±standard deviations (SD).
Multiple comparisons between groups were performed
using one-way analysis of variance with a post-hoc
Bonferroni test correction (SPSS 11.0 for Windows; SPSS
Inc., Chicago, IL, USA). Differences between groups were
deemed to be statistically significant at p<0.05.  
RESULTS
Effect of DPO on renal function in cisplatin
nephrotoxicity
Cisplatin injection significantly increased blood urea
nitrogen (BUN) and serum creatinine levels 96 h after
injection. In contrast, intraperitoneal injection of DPO in
cisplatin-injected rats significantly reduced BUN and
serum creatinine levels, compared to rats treated with
cisplatin alone (BUN, 143±25 mg/dL and creatinine,
3.9±0.2 mg/dL vs. BUN, 87.5±22.7 mg/dL and creatinine,
2.2±0.3 mg/dL, p<0.01, Fig. 1).
Effect of DPO on renal histology in cisplatin
nephrotoxicity
Histological examination revealed loss of brush border,
vacuolation, and desquamation of epithelial cells in renal
tubular epithelium 96 h after injection in cisplatin-only
treated rats. In contrast, treatment with DPO significantly
improved cisplatin nephrotoxicity histologically (Fig. 2). 
Anti-inflammatory and anti-apoptotic effects of
DPO in cisplatin nephrotoxicity
In the reverse transcription RT-PCR analysis of
inflammation- and apoptosis-related genes, expression of
TNF-α increased significantly in kidneys of cisplatin-
Figure 3. Semiquantitative analysis real-time PCR of TNF-α, Fas, Bcl-2, and MCP-1. TNF-α, Fas, and MCP-1 mRNA were over-
expressed in kidneys of cisplatin-injected rats, which was down-regulated by DPO treatment. Bcl-2 mRNA expression in kidneys of
cisplatin-injected rats significantly increased with DPO treatment. C, saline control; DPO, erythropoietin only; CIS, cisplatin;
CIS+DPO, DPO-treated cisplatin-injected group. *p<0.01 vs. saline, 
†p<0.05 vs. cisplatin.
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injected rats, compared to those of untreated and DPO-
only treated rats (5.1±0.9 vs. 1.2±0.1, p<0.01). There were
no differences in TNF-α mRNA expression between
untreated and DPO-only treated rats. Treatment with
DPO reversed the increased TNF-α mRNA expression in
kidneys of cisplatin-injected rats (5.1±0.9 vs. 2.4±1.1,
p<0.05). The expression of Fas increased significantly in
kidneys of cisplatin-injected rats, compared to those of
untreated and DPO-only treated rats (7.0±2.3 vs. 1.2±0.2,
p<0.01). Treatment with DPO reversed the increased Fas
mRNA expression in kidneys of cisplatin-injected rats
(7.0±2.3 vs. 1.4±0.6, p<0.05). DPO treatment significantly
increased Bcl-2 mRNA expression in kidneys of cisplatin-
injected rats (1.3±0.4 vs. 4.3±1.6 OD, p<0.05). MCP-1
mRNA expression was significantly higher in the
cisplatin-injected rats than in untreated and DPO-only
treated rats (6.6±1.2 vs. 1.2±0.1, p<0.01), but was
significantly down-regulated in DPO-treated cisplatin-
injected rats (6.6±1.2 vs. 2.7±1.5, p<0.05). No difference
in MCP-1 mRNA expression was detected in the kidneys
of untreated and DPO-only treated rats (Fig. 3).
Immunoblotting showed that caspase-3 activity increase
significantly in cisplatin-injected kidneys compared to
untreated and DPO only treated kidneys (53.2±8.2% vs.
14.6±1.9%, OD, p<0.01). DPO administration significantly
lowered the elevated caspase-3 activity in cisplatin-
injected rats (53.2±8.2% vs. 27.0±8.8%, OD, p<0.01),
while no difference in caspase-3 activity was detected
between untreated and DPO-only treated rats (Fig. 4).
DPO treatment significantly decreased the number of
TUNEL positive cells in cisplatin-treated rats (70.8±30.8
vs. 21.5± 8.3, p<0.01, Fig. 5).
Effect of DPO on hematocrit
The hemoglobin of DPO-treated group and DPO and
cisplatin-treated group increased significantly compared
with untreated rats. However, there was no significant
difference in hemoglobin among the three groups (data
not shown). 
DISCUSSION
We demonstrated that DPO has a renoprotective effect
Figure 4. (A) Densitometric analysis of immunoblotting of active caspase-3. DPO treatment resulted in suppression of active
caspase-3. (B) Representative photomicrographs of immunostaining of active caspase-3. DPO significantly decreased
immunoreactivity of active caspase-3. C, saline control; DPO, erythropoietin only; CIS, cisplatin; CIS+DPO, DPO-treated cisplatin-
injected group. *p<0.001 vs. saline, 
†p<0.01 vs. cisplatin.
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on cisplatin nephrotoxicity in rat kidneys, by attenuating
inflammation and apoptosis of renal tubular epithelial
cells.  The pathogenesis of renal injury by cisplatin is
associated with oxidative stress, inflammation, and
apoptosis [2]. Apoptosis is an important mode of cell
death in cisplatin nephrotoxicity. Engagement of a cell
surface receptor with extracellular TNF-α activates
caspase 8 [15]. Activated caspases 1, 8, and 9 are initiator
caspases that activate caspase 3, the principal executioner
caspase in renal tubule apoptosis. Additionally, while
cisplatin can induce Fas clustering into the membrane
lipid rafts and induce an apoptosis cascade in the absence
of Fas ligand in cancer cells, whether it is involved in
nephrotoxicity is unknown [16]. Inflammation also helps
Figure 5. Effect of DPO on apoptosis of renal tubular cells in
cisplatin injected rats. (A) Representative photomicrographs
of TUNEL (C, saline control; DPO, DPO only; CIS, cisplatin;
CIS+ DPO, DPO-treated cisplatin-injected. Original magni-
fication, 400×) and (B) quantitative analysis of TUNEL-
positive cells (arrows). *p<0.01 vs. saline, 
†p<0.01 vs. cisplatin.
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mediate cisplatin-induced renal injury. Ramesh and
Reeves [17] showed that TNF-α may play an important
role in inflammation and apoptosis in renal tubular
epithelial cells in cisplatin nephrotoxicity models. They
also demonstrated that a TNF-α-neutralizing antibody
had protective effects on a cisplatin nephrotoxicity model
[18]. As potent inflammatory markers, MCP-1 and TGF-β
are also increased in the kidney by cisplatin  [19]. 
DPO is a hyperglycosylated analog of recombinant
human erythropoietin that exhibits the same mechanism
of action as erythropoietin but a three-fold longer terminal
half-life after intravenous administration in both animal
models and humans [20]. It is as effective as EPO, with a
similar safety profile and less frequent dosing, in anemia
associated with chronic renal failure [21]. If it were
demonstrated to exhibit similar effects as those observed
with EPO, this would suggest that it has a pharmacokinetic
profile that would be clinically advantageous in ARF,
acute renal failure. 
EPO has protective effects on acute kidney injury. Both
low-dose (300 U/kg) and high-dose EPO (5000 U/kg)
have renal protective effects in ischemiareperfusion injury
[14,22,23]. DPO has a tissue-protective effect at low
(2 µg/kg) and high (30 µg/kg) doses in cardiac ischemia-
reperfusion models [24]. Both delayed treatment and
pretreatment of DPO (25 ug/kg) have renoprotective
effects on renal ischemia-reperfusion injury [14].
EPO’s anti-apoptotic effects are mediated via activation
of JAK-2 and subsequent nuclear translocation of NF-κB
and transcription of anti-apoptotic genes, including
expression of Bcl-XL and X-linked inhibitor of apoptosis.
An additional protective mechanism is an anti-apoptotic
effect via activation of PI3K/Akt and of STAT-family
transcriptional factor. The anti-inflammatory action of
EPO leads to the suppression of TNF-α and MCP-1 in
cerebral ischemia and autoimmune encephalomyelitis
models [25,26]. 
Although DPO has effects that are similar to EPO, the
renal protective mechanism(s) of DPO remain unclear.
DPO ameliorates apoptosis in porcine tubular and murine
mesangial cells induced by toxic and hypoxic stimuli [27].
The anti-apoptotic effect of DPO may be associated with
Bax protein suppression and prolonged Akt activation [14].
In a cisplatin nephrotoxicity model, Vaziri et al. [28]
reported that EPO may act directly by stimulating tubular
cell regeneration.  
In the present study, DPO treatment suppressed
caspase-3 protein levels and TUNEL-positive cells in the
kidneys of cisplatin nephrotoxicity rats. This may suggest
that DPO exerts anti-apoptotic effects. The potential
protective mechanisms of DPO include decreased expres-
sion of pro-apoptotic TNF-α, and increased expression
of anti-apoptotic Bcl-2, as assessed using real-time RT-
PCR. These results suggest that the renoprotective effect
of DPO in cisplatin nephrotoxicity occurs at least partly
by reducing apoptosis. These results are consistent with
previous observations of anti-apoptotic effects of DPO in
ischemic ARF in vivo [14] and in mouse mesangial cells
subjected to toxic stimuli [27]. DPO suppressed the
expression of MCP-1 in kidneys of rats with cisplatin
nephrotoxicity. This suggests that DPO treatment also
suppressed the inflammatory process caused by cisplatin.
We found significant increases in hematocrit over the
5day study period in animals receiving DPO. Although a
hemopoietic response may have a potentially beneficial
effect by increasing oxygencarrying capacity, it may also
harm kidneys by enhancing thrombotic potential [29].
However, previous in vitro studies are consistent with the
beneficial effects of EPO in acute kidney injury being
independent of its hemopoietic actions [10,27].
Additionally, asialoerythropoietin, which is generated by
the enzymatic desialylation of EPO, provides neuropro-
tection without changing the hematocrit. Thus, there is
evidence for tissue-protective effects of EPO independent
of hematocrit. 
In conclusion, our study demonstrates that inflammation
and apoptosis may be involved in the mechanism of
kidney injury in cisplatin nephrotoxicity. We showed that
DPO has a renoprotective effect against inflammation and
apoptosis in the kidneys of cisplatin-treated rats. 
REFERENCES
1. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy
with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986;
8:368-379.
2. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephro-
toxicity: a review. Am J Med Sci 2007;334:115-124.
3. Francescato HD, Costa RS, Scavone C, Coimbra TM. Parthenolide
reduces cisplatin-induced renal damage. Toxicology 2007;230:
64-75.
4. Iseri S, Ercan F, Gedik N, Yuksel M, Alican I. Simvastatin attenuates
cisplatin-induced kidney and liver damage in rats. Toxicology
2007;230:256-264.
5. Engineer MS, Brown NS, Ho DH, Newman RA, Bulger RE. A
comparison of the effects of tetraplatin and cisplatin on renal246 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
function and gentamicin pharmacology in rats. Toxicology
1989;59:151-162.
6.Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A.
Effects of lycopene against cisplatin-induced nephrotoxicity and
oxidative stress in rats. Toxicology 2005;212:116-123.
7. Bernaudin M, Marti HH, Roussel S, et al. A potential role for
erythropoietin in focal permanent cerebral ischemia in mice. J
Cereb Blood Flow Metab 1999;19:643-651.
8.Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin
attenuates the tissue injury associated with hemorrhagic shock
and myocardial ischemia. Shock 2004;22:63-69.
9. Bogoyevitch MA. An update on the cardiac effects of erythropoietin
cardioprotection by erythropoietin and the lessons learnt from
studies in neuroprotection. Cardiovasc Res 2004;63:208-216.
10.Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW.
Erythropoietin protects against ischaemic acute renal injury.
Nephrol Dial Transplant 2004;19:348-355.
11. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances
recovery after cisplatin-induced acute renal failure in the rat.
Nephrol Dial Transplant 2001;16:932-938.
12. Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation
and fibrosis by recombinant human erythropoietin in chronic
cyclosporine nephropathy. Am J Nephrol 2005;25:64-76.
13. Macdougall IC. Novel erythropoiesis stimulating protein. Semin
Nephrol 2000;20:375-381.
14. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed
administration of darbepoetin or erythropoietin protects against
ischemic acute renal injury and failure. Kidney Int 2006;69:1806-
1813.
15. Tsuruya K, Ninomiya T, Tokumoto M, et al. Direct involvement of
the receptor-mediated apoptotic pathways in cisplatin-induced
renal tubular cell death. Kidney Int 2003;63:72-82.
16. Dimanche-Boitrel MT, Meurette O, Rebillard A, Lacour S. Role of
early plasma membrane events in chemotherapy-induced cell
death. Drug Resist Updat 2005;8:5-14.
17. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced
nephrotoxicity is mediated by tumor necrosis factor-alpha
produced by renal parenchymal cells. Kidney Int 2007;72:37-44.
18. Premkumar K, Abraham SK, Santhiya ST, Ramesh A. Inhibitory
effects of aqueous crude extract of Saffron (Crocus sativus L.) on
chemical-induced genotoxicity in mice. Asia Pac J Clin Nutr
2003;12:474-476.
19. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and
cytokine expression and renal injury in cisplatin nephrotoxicity. J
Clin Invest 2002;110:835-842.
20.Locatelli F, Vecchio LD. Darbepoetin alfa: amgen. Curr Opin
Investig Drugs 2001;2:1097-1104.
21. Smith RE Jr, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis
stimulating protein (NESP) for the treatment of anaemia of
chronic disease associated with cancer. Br J Cancer
2001;84(Suppl 1):24-30.
22.Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin
protects against subsequent ischemia-reperfusion injury in rat
kidney. FASEB J 2003;17:1754-1755.
23.Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the
kidney against the injury and dysfunction caused by ischemia-
reperfusion. J Am Soc Nephrol 2004;15:2115-2124.
24.Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch
WJ. Darbepoetin alfa, a long-acting erythropoietin analog, offers
novel and delayed cardioprotection for the ischemic heart. Am J
Physiol Heart Circ Physiol 2007;293:H60-H68.
25.Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively
attenuates cytokine production and inflammation in cerebral
ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:
971-975.
26.Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an anti-
inflammatory effect on the CNS in a model of experimental
autoimmune encephalomyelitis. Brain Res 2002;952:128-134.
27.Fishbane S, Ragolia L, Palaia T, Johnson B, Elzein H, Maesaka
JK. Cytoprotection by darbepoetin/epoetin alfa in pig tubular and
mouse mesangial cells. Kidney Int 2004;65:452-458.
28.Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery
from cisplatin-induced acute renal failure. Am J Physiol 1994;
266:F360-F366.
29.Casserly LF, Dember LM. Thrombosis in end-stage renal disease.
Semin Dial 2003;16:245-256.